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Leicester University, Clinical Sciences Building, Leicester Royal Infirmary, Leicester, UKObjective. Intimal hyperplasia (IH) threatens the patency of up to 35% of saphenous vein (SV) bypass grafts. In addition to
reducing cholesterol levels, statins may modulate smooth muscle cell proliferation and migration. Statins inhibit matrix
metalloproteinase (MMP) activity. We therefore investigated the effect of six statins on neointimal formation and MMP
activity in human SV organ culture.
Study design. Human SV specimens were cultured for 14 days in the presence of six different statins and subsequently
processed for measurement of neointimal thickness and MMP activity. The drug concentrations chosen corresponded to the
manufacturers’ Cmax.
Results. The six statins all significantly reduced IH development (PZ0.004) in association with reduced expression of
proMMP-2 and 9 (PZ0.03) and reduced activity of activated MMP-2 and 9 (PZ0.03).
Conclusion. This study suggests that the potential benefit of statins in reducing IH is a class effect and not confined to
specific statins. The reduction of IH produced by statins may in part be due to their inhibition of MMPs.Keywords: Intimal hyperplasia; Saphenous vein; MMPs; Organ culture.Introduction
Intimal hyperplasia (IH) is a significant cause of
peripheral and coronary vascular bypass grafts fail-
ure1 and although several pharmacological
approaches have been shown to reduce IH in animal
models, these results have not been reproduced in
human clinical trials. One of the key pathological
processes in the development of IH is the proliferation
of smooth muscle cells (SMC’s) and their migration
into the subintimal space with subsequent synthesis of
extracellular matrix (ECM). A prerequisite for SMC
migration is the degradation of surrounding matrix
proteins, a process accomplished by secretion of
specific matrix-degrading enzymes (MMPs) by the
SMCs themselves.2–5
Statins are a class of drugs used to reduce plasma
cholesterol levels in patients with hypercholesterole-
mia.6 Large clinical trials have shown that the
beneficial effects of statins in patients with athero-
sclerotic disease are attributable to the inhibition ofing author. Prof N.J.M. London, Department of
ester University, Clinical Sciences Building, Leicester
ry, Leicester LE2 7LX, UK.
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cholesterol biosynthesis.7–10 Laufs and colleagues11
have shown that some of the effects of HMG-CoA
reductase inhibitors on SMC are independent of their
effects on plasma cholesterol levels, probably through
inhibition of isoprenoid synthesis which is a precursor
of prenylated proteins.11 Corsini and colleagues12 have
shown that statins can decrease rat aortic SMC
migration and proliferation by interfering with signal-
ling pathways requiring prenylated proteins. We have
previously shown that simvastatin inhibits human
saphenous vein neointima formation in an organ
culture model.13,14 The purpose of this study was to
investigate whether this effect was limited to simvas-
tatin or whether six different statins were equally
effective in this respect. In addition the effect of the six
statins on tissue levels of pro and activated MMP2 and
MMP9 was measured.MethodsOrgan culture
Segments of long saphenous vein were obtained fromEur J Vasc Endovasc Surg 29, 177–181 (2005)
doi:10.1016/j.ejvs.2004.11.003, available online at http://www.sciencedirect.com onved.
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grafting and prepared for culture by a method
described previously.13 Local ethical committee
approval and patient consent were obtained. For
each patient, four segments were cultured in RPMI-
1640 medium supplemented with 30% foetal calf
serum for a period of 14 days. One segment served
as control, and in the first group the remaining three
were supplemented with simvastatin (Merck, Sharpe
and Dohme) at concentration of 1 mmol/l, lovastatin
(Merck, Sharpe and Dohme) at concentration of
1 mmol/l, fluvastatin (Novartis) at concentration of
0.1 mmol/l. In the second group, the same procedure
was followed but using a control compared with
atorvastatin (Pfizer) at concentration of 1 mmol/l,
cerivastatin (Bayer) at concentration of 0.1 mmol/l,
and pravastatin (Bristol-Myers Squibb) at concentration
of 1 mmol/l. These drug concentrations were chosen
because they corresponded with the manufacturers’
Cmax in patients. Simvastatin and lovastatin were both
activated by dissolving in absolute ethanol (95–100%) to
which was added 0.6 M sodium hydroxide and heating
at 60 8C for 2 h. This solutionwas thenadjusted topH7.4
by the addition 0.1 M hydrochloric acid.
Culture medium and drugs were replaced every 2
days and at the end of the culture period the segments
were divided in half. One half was fixed in 4%
paraformaldehyde for 18 h, processed, paraffin-
embedded and sectioned to 4 mm. The remaining half
was immediately snap-frozen in liquid nitrogen and
stored at K80 8C for subsequent metalloproteinase
extraction and gelatin zymography.Immunohistochemistry and neointimal measurements
Standard morphometric measurements were per-
formed on histological cross sections of cultured vein
segments stained with anti-alpha smoothmuscle actin.
This method uses and indirect immunoperoxidase
technique, with diaminobenzidine as the final reaction
product. This was followed by application of Millers
elastin stain to localise the internal elastic lamina. The
neointimal thickness was determined by making an
average of 30 measurements across the entire length of
two sections of each vein segment as previously
described.13 This gave 60 measurements for each
vein segment and the mean value of these 60
measurements gave a single neointimal measurement
for each vein segment.Gelatin zymography
Metalloproteinases were extracted from the frozenEur J Vasc Endovasc Surg Vol 29, February 2005tissues by a method described previously15 and
protein standardised to 0.9 mg/ml. Zymography was
performed on each sample by non-reducing electro-
phoresis through a 10% SDS-polyacrylamide gel
impregnated with 1 mg/ml gelatin.15 As a positive
control, conditioned medium from a human fibrosar-
coma cell line (HT-1080) was also loaded onto each gel.
On completion of the separation, sodium dodecylsul-
fate was removed from the gels with incubation in
2.5% Triton X-100 (3! 15 min) (Sigma, Poole, UK)
before immersion for 18 h in incubation buffer
(50 mmol/l Tris–HCl, 10 mmol/l CaCl2, and 0.05%
Brij-35, pH 7.4) at 37 8C. Gels then were fixed and
stained in 0.1% Coomassie Brilliant blue (Sigma) in
50% methanol/20% acetic acid/30% double distilled
water for 2–3 h. Proteinases were visualised as clear
bands of lysis against a dark background of intact
substrate. The molecular weight of each band was
estimated by comparison with known molecular
weight standards (Bio-Rad, Hemel Hempstead,
Herts; UK). The relative density of each lytic band
was determined from negative photographic images
of gels using a scanning densitometer (Pharmacia
LKB, St Albans, Herts; UK) and expressed as a product
of optical density and area of the band. To allow for
variation between gels samples from within the same
experimental group were run on the same gel and
paired statistics used in the analysis.Data analysis
For the neointimal thickness and zymography quanti-
fication, paired analysis between groups was initially
explored using non-parametric ANOVA (the Fried-
man test). If there were significant differences within
the groups the only further comparisons made were
between control and the six statins. This was done
using the Wilcoxon paired rank test and significance
was assumed at P!0.05. We did not examine
differences between statins because the number of
experiments performed did not justify such multiple
comparisons. All statistical analyses were performed
using GraphPad Prism version 3.02 for Windows
(GraphPad Software, San Diego, CA).ResultsEffect of statins on neointimal thickness
All control veins developed a significant neointima,
with a median thickness of 16.9 mm. The median and
range of neontimal measurements for the control and
Statins and IH 179six statins are given in Table 1. Fig. 1 shows the same
results expressed as a percentage reduction in IH
compared to the control vein. The reduction in
neointimal thickness compared to control was statisti-
cally significant at the PZ0.004 level for all six statins.Fig. 1. Percentage reduction in IH compared to the control
for the six statins. The bar represents the median. The
reduction in neointimal thickness compared to control was
significant at the PZ0.004 level for all six statins.Effect of statins on MMP tissue levels
The effect of the six statins on tissue levels of proMMP-
2, activated MMP-2, proMMP-9, and activated MMP-9
are shown in Figs. 2–5, respectively. The results are
expressed as a ratio of the levels observed in control
vein. The reduction in proMMP-2, activated MMP-2,
proMMP-9 and activated MMP-9 levels was signifi-
cant for all six statins at the PZ0.03 level.Discussion
Although all statins inhibit the HMG-CoA reductase
pathway, they vary in the extent that they inhibit sterol
synthesis in human smooth muscle cells16 and have
differing clinical pharmacokinetics.12 In particular
cerivistatin and pravastatin are relatively hydrophilic.
In vitro studies of isolated human SMC proliferation
have shown that cerivistatin is the strongest inhibitor
of proliferation with pravastatin being the weakest.16
The latter finding may relate to the hydrophilicity of
pravastatin.17 A comparison of the six statins on rat
SMC migration found that all the statins except
pravastatin inhibited migration.17 A clinical study18
of statin therapy on restenosis after coronary stent
implantation reported a highly significant reduction in
angiographic restenosis in patients taking statins (25
versus 38%). However, this study lacked sufficient
power to detect whether this beneficial outcome was a
class effect of HMG-CoA reductase inhibitors or was
confined to specific statins.
The statins in these experiments were used at
concentrations corresponding to their Cmax and all
produced a significant reduction of IH development in
a human saphenous vein organ culture. We also found
a significant reduction in proMMP-2, proMMP-9,Table 1. Median and range intimal hyperplasia thickness for
control and statin exposed veins
Median (mm) Range (mm)
Control 17 14–19
Simvastatin 6 5–10
Lovastatin 6 5–10
Fluvastatin 6 5–10
Atorvastatin 7 6–11
Cerivastatin 8 6–10
Pravastatin 10 7–11activated MMP-2 and activated MMP-9 tissue levels
in vein segments cultured in the presence of all six
statins. The effect of simvastatin on IH development
and tissue levels of MMPs in human saphenous vein
organ culture has previously been reported by Porter
et al.14 who found that simvastatin reduced IH and
reduced tissue levels of MMPs. Porter et al. found that
simvastatin inhibited isolated human SMC prolifer-
ation and migration and proposed that these effects
led to reduced IH in organ culture.
Although normal SMC do not produce MMP under
quiescent conditions, they can be stimulated to do so
under conditions of injury. This was demonstrated by
George and colleagues who showed that surgical
preparation of saphenous vein increased the level of
MMP-2 and 9 activity19 and it has been shown that
MMP-2 and MMP-9 levels are increased during organ
culture of saphenous vein.20 Our finding that statins
reduce MMP levels support those of Porter et al.14 and
suggest that one of the beneficial actions of statins is toFig. 2. Tissue levels of proMMP-2 for the six statins
expressed as a percentage of the level in control vein. The
bar represents the median. The levels of proMMP-2 for all six
statins are significantly less than control levels at PZ0.03.
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Fig. 3. Tissue levels of activated MMP-2 for the six statins
expressed as a percentage of the level in control vein. The bar
represents the median. The levels of activated MMP-2 for all
six statins are significantly less than control levels at PZ0.03.
Fig. 5. Tissue levels of activated MMP-9 for the six statins
expressed as a percentage of the level in control vein. The bar
represents the median. The levels of activated MMP-9 for all
six statins are significantly less than control levels at PZ0.03.
J.-M. Corpataux et al.180reduce SMC migration via inhibition of MMP activity.
Interestingly, a recent clinical study21 found that
pravastatin treatment reduced serum levels of MMP-9.
Statins may also inhibit SMC function by inhibition
of intracellular mechanisms. HMG-CoA reductase is a
key enzyme in the mevalonate pathway, which in
addition to its central role in cholesterol synthesis is
also an important precursor of many isoprenoid
compounds, including farnesyl pyrophosphate (FPP)
and geranylgeranyl pyrophosphate (GGPP). Both FPP
and GGPP are required for prenylation of small G-
proteins22 including the Ras and Rho families. Ras and
Rho regulate gene expression and Rho is also
important for cytoskeletal reorganization. Several
studies have suggested that the inhibitory effects of
statins on vascular SMC proliferation and migration
are due to inhibition of the prenylation of either Ras or
Rho.11,23–28
Cerivastatin was withdrawn from clinical practice
in August 2001 because of concerns about severeFig. 4. Tissue levels of proMMP-9 for the six statins
expressed as a percentage of the level in control vein. The
bar represents the median. The levels of proMMP-9 for all six
statins are significantly less than control levels at PZ0.03.
Eur J Vasc Endovasc Surg Vol 29, February 2005myopathy. However, the remaining five statins are still
widely used. All patients with symptomatic periph-
eral vascular disease should be on a statin.10 Currently
there are not any trials that suggest that any one
particular statin is more efficacious than another with
respect to cardiovascular risk reduction. The choice of
statin is therefore determined by considerations such
as cost and potential drug interactions. Although any
conclusions drawn from our study have to be guarded
because of its in vitro nature, it would seem that all six
statins examined markedly reduce IH and that this
effect is a class effect rather than drug specific.Acknowledgements
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